Press release -

Sobi submits application for Orfadin® oral suspension to EMA

Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company's application for Orfadin oral suspension has been validated by the European Medicines Agency (EMA). This new dosage form has been developed to facilitate the ease and accuracy in administration of the desired Orfadin dose to paediatric patients and to increase convenience for the patients and their caregivers.

"We are glad that our application for the Orfadin oral suspension has been accepted by EMA", said Birgitte Volck, Senior Vice President and Chief Medical Officer at Sobi. "The liquid formulation of Orfadin will facilitate precise dosing for children and should also help increase adherence which is key in any successful treatment."

The oral suspension is included in a Paediatric Investigation Plan (PIP) agreed with EMA in March 2012.

---

About Orfadin
Orfadin is used for the treatment of hereditary tyrosinemia type 1 (HT-1), a rare genetic disorder which can cause liver failure, kidney dysfunction and neurological problems.

For more information - not for publication

Media relationsInvestor relations
Oskar Bosson, Head of CommunicationsJörgen Winroth, Vice President, Head of Investor Relations
T: +46 70 410 71 80T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson@sobi.comjorgen.winroth@sobi.com

Topics

  • Health, Health Care, Pharmaceuticals

Categories

  • sobi
  • orfadin®

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflamma-tion and Genetic diseases, with three late stage biological development projects within Haemophilia and Neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More infor-mation is available at www.sobi.com.

Contacts

Charlotte af Klercker

Press contact Senior Communications Manager 0707-297327

Related media

Sobi submits application for Orfadin® oral suspension to EMA
  • Sobi submits application for Orfadin® oral suspension to EMA
  • License: Media Use
    The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
  • File format: .pdf
Download

Related content

Sobi assumes direct responsibility for Orfadin® (nitisinone) in US and Canada and introduces Orfadin4U

Sobi today assumed direct responsibility for the distribution of its proprietary product Orfadin in the United States and Canada. Orfadin is the only FDA approved therapy for the treatment of hereditary tyrosinaemia type 1 (HT-1). Sobi has been responsible for the worldwide development and commercialisation of Orfadin since 1993.

Early treatment and a longer life – new Orfadin formats meet new patient needs

The Committee for Medicinal Products for Human Use (CHMP) of EMA has adopted a positive opinion for the oral suspension formulation and the 20 mg capsule of Orfadin® for the treatment of Hereditary Tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.

European Commission approves Orfadin® oral suspension

The European Commission has approved the oral suspension formulation of Orfadin® (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) as of 19 June 2015. “The new oral suspension formulation is a demonstration of Sobi’s commitment to the needs of the infants and children diagnosed with HT-1 early in life,” says Birgitte Volck, Chief Medical Officer of Sobi.